Biologic Therapy

FDA Reviews Biologics License Application for Novel Migraine Prevention Treatment

FDA Reviews Biologics License Application for Novel Migraine Prevention Treatment

By

The Food and Drug Administration has accepted a Biologics License Application for the investigational migraine prevention treatment, galcanezumab.

Juvenile Idiopathic Arthritis: Risk Factors for Infection of Biologic Therapy

Juvenile Idiopathic Arthritis: Risk Factors for Infection of Biologic Therapy

By

Patients with juvenile idiopathic arthritis receiving biologic therapy have high rates of serious infections.

Sign Up for Free e-Newsletters